Direct Oral Anticoagulants in Cardioversion

A Review of Current Evidence

Research output: Contribution to journalReview articleResearchpeer-review

3 Citations (Scopus)

Abstract

Objective: Direct oral anticoagulants (DOACs) are recommended for the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation. Dabigatran, rivaroxaban, apixaban, and edoxaban represent possible alternatives to warfarin in the setting of cardioversion. A literature review was conducted to evaluate the safety and efficacy of DOAC use pericardioversion. Data Sources: A PubMed and MEDLINE search through August 2017 was conducted using the following search terms alone or in various combinations: dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban, DOAC, NOAC, TSOAC, cardioversion. Study Selection and Data Extraction: All English-language, human studies comparing the safety and efficacy of DOACs with that of other anticoagulants in the setting of cardioversion were eligible for inclusion. References from published articles were reviewed for additional relevant citations for study inclusion. Four retrospective and 2 prospective trials comparing DOACs with warfarin were identified. Data Synthesis: The majority of studies included patients undergoing electric cardioversion. Based on current evidence, the DOACs perform similarly to warfarin in the prevention of stroke and systemic embolism, and bleeding rates are comparable. Conclusions: DOACs may be an attractive alternative to warfarin because of fast onset of action, potentially reducing delay to cardioversion. More robust studies are needed in patients with renal dysfunction and patients undergoing pharmacological cardioversion.

Original languageEnglish
Pages (from-to)277-284
Number of pages8
JournalAnnals of Pharmacotherapy
Volume52
Issue number3
DOIs
StatePublished - 1 Mar 2018

Fingerprint

Electric Countershock
Anticoagulants
Warfarin
Embolism
Stroke
Safety
Information Storage and Retrieval
PubMed
MEDLINE
Atrial Fibrillation
Language
Pharmacology
Hemorrhage
Kidney

Keywords

  • anticoagulation
  • apixaban
  • atrial fibrillation
  • cardioversion
  • dabigatran
  • direct oral anticoagulants
  • edoxaban
  • rivaroxaban
  • warfarin

Cite this

@article{a9f441e461f04d038277c50863109eeb,
title = "Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence",
abstract = "Objective: Direct oral anticoagulants (DOACs) are recommended for the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation. Dabigatran, rivaroxaban, apixaban, and edoxaban represent possible alternatives to warfarin in the setting of cardioversion. A literature review was conducted to evaluate the safety and efficacy of DOAC use pericardioversion. Data Sources: A PubMed and MEDLINE search through August 2017 was conducted using the following search terms alone or in various combinations: dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban, DOAC, NOAC, TSOAC, cardioversion. Study Selection and Data Extraction: All English-language, human studies comparing the safety and efficacy of DOACs with that of other anticoagulants in the setting of cardioversion were eligible for inclusion. References from published articles were reviewed for additional relevant citations for study inclusion. Four retrospective and 2 prospective trials comparing DOACs with warfarin were identified. Data Synthesis: The majority of studies included patients undergoing electric cardioversion. Based on current evidence, the DOACs perform similarly to warfarin in the prevention of stroke and systemic embolism, and bleeding rates are comparable. Conclusions: DOACs may be an attractive alternative to warfarin because of fast onset of action, potentially reducing delay to cardioversion. More robust studies are needed in patients with renal dysfunction and patients undergoing pharmacological cardioversion.",
keywords = "anticoagulation, apixaban, atrial fibrillation, cardioversion, dabigatran, direct oral anticoagulants, edoxaban, rivaroxaban, warfarin",
author = "Gibson, {Caitlin Marie} and Basto, {Amanda N.} and Meredith Howard",
year = "2018",
month = "3",
day = "1",
doi = "10.1177/1060028017737095",
language = "English",
volume = "52",
pages = "277--284",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "SAGE Publications Inc.",
number = "3",

}

Direct Oral Anticoagulants in Cardioversion : A Review of Current Evidence. / Gibson, Caitlin Marie; Basto, Amanda N.; Howard, Meredith.

In: Annals of Pharmacotherapy, Vol. 52, No. 3, 01.03.2018, p. 277-284.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Direct Oral Anticoagulants in Cardioversion

T2 - A Review of Current Evidence

AU - Gibson, Caitlin Marie

AU - Basto, Amanda N.

AU - Howard, Meredith

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: Direct oral anticoagulants (DOACs) are recommended for the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation. Dabigatran, rivaroxaban, apixaban, and edoxaban represent possible alternatives to warfarin in the setting of cardioversion. A literature review was conducted to evaluate the safety and efficacy of DOAC use pericardioversion. Data Sources: A PubMed and MEDLINE search through August 2017 was conducted using the following search terms alone or in various combinations: dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban, DOAC, NOAC, TSOAC, cardioversion. Study Selection and Data Extraction: All English-language, human studies comparing the safety and efficacy of DOACs with that of other anticoagulants in the setting of cardioversion were eligible for inclusion. References from published articles were reviewed for additional relevant citations for study inclusion. Four retrospective and 2 prospective trials comparing DOACs with warfarin were identified. Data Synthesis: The majority of studies included patients undergoing electric cardioversion. Based on current evidence, the DOACs perform similarly to warfarin in the prevention of stroke and systemic embolism, and bleeding rates are comparable. Conclusions: DOACs may be an attractive alternative to warfarin because of fast onset of action, potentially reducing delay to cardioversion. More robust studies are needed in patients with renal dysfunction and patients undergoing pharmacological cardioversion.

AB - Objective: Direct oral anticoagulants (DOACs) are recommended for the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation. Dabigatran, rivaroxaban, apixaban, and edoxaban represent possible alternatives to warfarin in the setting of cardioversion. A literature review was conducted to evaluate the safety and efficacy of DOAC use pericardioversion. Data Sources: A PubMed and MEDLINE search through August 2017 was conducted using the following search terms alone or in various combinations: dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban, DOAC, NOAC, TSOAC, cardioversion. Study Selection and Data Extraction: All English-language, human studies comparing the safety and efficacy of DOACs with that of other anticoagulants in the setting of cardioversion were eligible for inclusion. References from published articles were reviewed for additional relevant citations for study inclusion. Four retrospective and 2 prospective trials comparing DOACs with warfarin were identified. Data Synthesis: The majority of studies included patients undergoing electric cardioversion. Based on current evidence, the DOACs perform similarly to warfarin in the prevention of stroke and systemic embolism, and bleeding rates are comparable. Conclusions: DOACs may be an attractive alternative to warfarin because of fast onset of action, potentially reducing delay to cardioversion. More robust studies are needed in patients with renal dysfunction and patients undergoing pharmacological cardioversion.

KW - anticoagulation

KW - apixaban

KW - atrial fibrillation

KW - cardioversion

KW - dabigatran

KW - direct oral anticoagulants

KW - edoxaban

KW - rivaroxaban

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=85041432548&partnerID=8YFLogxK

U2 - 10.1177/1060028017737095

DO - 10.1177/1060028017737095

M3 - Review article

VL - 52

SP - 277

EP - 284

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 3

ER -